50th ASH Annual Meeting and Exposition (December 6 - 9, 2008): Chronic Lymphocytic Leukemia - Biology and Pathophysiology, Excluding Therapy Poster I

Saturday, December 6, 2008: 5:30 PM-7:30 PM

Hall A (Moscone Center)

Array CGH Analysis of Chronic Lymphocytic Leukemia Reveals Frequent Cryptic Monoallelic and Biallelic Deletions of Chromosome 22q11

William D. McClain¹^*, Shelly R. Gunn¹^*, Aswani R. Bolla¹^*, Lynn L. Barron²^*, Mercedes E. Gorre³^*, David W. Bahler⁴, Clemens H. M. Mellink⁵^*, Marinus H. J. van Oers⁶, Michael J. Keating⁷, Alessandra Ferrajoli⁷, Kevin R. Coombes⁸^*, Lynne V Abruzzo, MD, PhD⁹ and Ryan S. Robetorye¹

¹Department of Pathology, University of Texas Health Science Center at San Antonio, San Antonio, TX
²Department of Hematopathology, U.T.M.D. Anderson Cancer Center, Houston, TX
³Combimatrix Molecular Diagnostics, Irvine, CA
⁴ARUP Laboratories, Salt Lake City, UT
⁵Department of Clinical Genetics, Academic Medical Center, Amsterdam, Netherlands
⁶Department of Hematology, Academic Medical Center, Amsterdam, Netherlands
⁷Department of Leukemia, U.T.M.D. Anderson Cancer Center, Houston, TX
⁸Department of Bioinformatics and Computational Biology, U.T.M.D. Anderson Cancer Center, Houston, TX
⁹Hematopathology, U.T.M.D. Anderson Cancer Center, Houston, TX

1051

ZAP-70 Intron-1 DNA Methylation Status: A Simplified Method of Determination by Pyrosequencing in B Chronic Lymphocytic Leukemia

Sylvain Chantepie, MD¹^*, Dominique Vaur, MD²^*, Christophe Grunau, PhD³^*, Veronique Salaun, MD⁴^*, Melanie Briand⁵^*, Stéphane Cheze, MD¹^*, Pascal Gauduchon, PhD⁵^*, Michel Leporrier, MD¹ and Sophie Krieger, PhD²^*

¹Clinical Hematology, CHU Caen, Caen, France
²Biology, Centre François Baclesse, Caen, France
³UMR 5244 CNRS, Perpignan, France
⁴Laboratory hematology, CHU Caen, Caen, France
⁵Grecan, Caen, France

1052

Telomere Length Is An Independent Predictor of Survival, Treatment Requirement and Richter's Syndrome Transformation in Chronic Lymphocytic Leukemia

Davide Rossi, MD¹, Chiara Lobetti Bodoni, MD²^*, Elisa Genuardi, PhD²^*, Luigia Monitillo, PhD²^*, Daniela Drandi, PhD²^*, Clara Deambrogi, PhD³^*, Michaela Cerri, PhD³^*, Irene Ricca, MD²^*, Alberto Rocci, MD²^*, Simone Ferrero, MD²^*, Elisa Bernocco, MD²^*, Daniela Capello, PhD³^*, Lorenzo De Paoli, MD³^*, Luciana Bergui, MD²^*, Michela Boi, PhD⁴^*, Paola Omedè, PhD²^*, Massimo Massaia, MD²^*, Corrado Tarella, MD²^*, Roberto Passera, PhD⁵^*, Mario Boccadoro, MD²^*, Gianluca Gaidano, MD³^* and Marco Ladetto, MD²

¹Italian Multiple Myeloma Network, GIMEMA, Italy
²Cattedra di Ematologia, Universita di Torino, Torino, Italy
³Dept. of Med. Sciences & IRCAD, Amedeo Avorgadro Univ., Novara, Italy
⁴Divisione di Ematologia dell'Università di Torino, A.O.U San Giovanni Battista, Torino, Italy
⁵Dipartimento Di Statistica, Ospedale San Giovanni Battista, Torino

1053

The Performance of Computed Tomography (CT) Scans or Ultrasound Has No Clinical Relevance in Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Metaanalysis from Three Phase III Studies of the German CLL Study Group (GCLLSG)

Barbara F. Eichhorst, MD¹, Kirsten Fischer, MD¹^*, Anna- Maria Fink, MD¹^*, Thomas Elter, MD¹^*, Clemens M Wendtner, MD¹, Raymonde Busch, Dipl., math.²^*, Michael Hallek¹ and German CLL Study Group³^*

¹Dept. I of Internal Med. , Centre of Integrated Oncology Köln Bonn, Univeristy of Cologne, Cologne, Germany
²Technical University, Institute for Medical Statistic and Epidemiology, Munich, Germany
³GCLLSG, Germany

1054

High CD79b Expression Predicts a Poor Outcome in B-Cell Chronic Lymphocytic Leukemia (B-CLL)

Giovanni Del Poeta¹, Maria Ilaria Del Principe¹^*, Antonella Zucchetto²^*, Francesco Buccisano¹^*, Cristina Simotti¹^*, Luca Maurillo¹^*, Laura Giannì¹^*, Pietro Bulian²^*, Adriano Venditti¹^*, Angela Coletta¹^*, Pasquale Niscola¹^*, Paolo de Fabritiis¹^*, Valter Gattei²^* and Sergio Amadori¹^*

¹Hematology, University Tor Vergata, Rome, Italy
²Clinical and Experimental Hematology Research Unit, Centro di Riferimento Oncologico, Aviano (PN), Italy

1055

CCL3 and CCL4, the Major Chemokines Produced by CD38+ Chronic Lymphocytic Leukemia Cells, Facilitate Microenvironmental Interactions of Neoplastic Cells Via the CD49d/VCAM Pair

Antonella Zucchetto¹^*, Dania Benedetti¹^*, Riccardo Bomben¹^*, Claudio Tripodo²^*, Fleur Bossi³^*, Michele Dal-Bo¹^*, Daniela Marconi¹^*, Massimo Degan¹^*, Giovanni Del Poeta⁴, Silvia Deaglio⁵^*, Francesco Tedesco³^*, Gianluca Gaidano⁶^*, Fabio Malavasi⁵^* and Valter Gattei¹^*

¹Clinical and Experimental Hematology Research Unit, Centro di Riferimento Oncologico, Aviano (PN), Italy
²Department of Human Pathology, University of Palermo, Italy
³Department of Fisiology and Pathology, University of Trieste, Italy
⁴Hematology, University Tor Vergata, Rome, Italy
⁵Department of Genetics, Laboratory of Immunogenetics, University of Turin, Italy
⁶Dept. of Med. Sciences & IRCAD, Amedeo Avorgadro Univ., Novara, Italy

1056

De Novo Deletion 17p13.1 Chronic Lymphocytic Leukemia Shows Significant Clinical Heterogeneity: The MD Anderson / Mayo Clinic Experience

Constantine S. Tam¹, Tait D. Shanafelt²^*, William G. Wierda³, Lynne V Abruzzo, MD, PhD⁴, Daniel L. Van Dyke⁵^*, Susan Lerner³^*, Alice Lynn³^*, Neil E. Kay²^* and Michael J Keating³^*

¹Haematology, St Vincent's Hospital, Fitzroy, Australia
²Hematology/Oncology division, Mayo Clinic, Rochester, MN
³Leukemia, UT MD Anderson Cancer Center, Houston, TX
⁴Hematopathology, U.T.M.D. Anderson Cancer Center, Houston, TX
⁵Mayo Clinic, Rochester, MN

1057

Predictors of Clinical Outcome to Pentostatin, Cyclophosphamide and Rituximab (PCR) Followed by Campath for Relapsed/Refractory CLL – A Study of the Eastern Cooperative Oncology Group, E2903

Neil E. Kay, MD¹, Haesook T Kim, Ph.D.²^*, Sanford Kempin, MD³, Charla Secreto¹^*, Traci Knox¹^*, Renee Tschumper¹^*, Diane F Jelinek¹^*, Stephanie Smoley¹^*, Daniel VanDyke¹^*, Joel Saltzman, MD⁴^*, Steven T. Rosen, MD⁵, Brad Kahl, MD⁶ and Martin S. Tallman, MD⁷

¹Mayo Clinic, Rochester, MN
²Dana-Farber Cancer Institute, Boston, MA
³Comprehensive Cancer Center, St. Vincent's Hospital, New York, NY
⁴Case Western Reserve University, Cleveland, OH
⁵Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago, IL
⁶University of Wisconsin, Madison, WI
⁷Northwestern University Feinberg School of Medicine, Chicago, IL

1058

STAT3 Is Constitutively Phosphorylated on Serine 727 Residues, Activates Transcription, and Plays a Major Role in the Pathogenesis of B-Cell Chronic Lymphocytic Leukemia

Inbal Hazan-Halevy, Ph.D.^*, David Harris^*, Zhiming Liu^*, Alessandra Ferrajoli, M.D.^*, Michael J Keating, M.D.^* and Zeev Estrov, M.D.

Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, TX

1059

Importin-β1 and Nucleus Transporter Chromosome Region Maintenance 1 (CRM1) Constitute the Nucleocytoplasmic Transport System of STAT3 in Blood-Derived CLL Cells

Inbal Hazan-Halevy, Ph.D.^*, David Harris^*, Zhiming Liu^*, Alessandra Ferrajoli, MD.^*, Michael J Keating, M.D.^* and Zeev Estrov, MD

Department of Leukemia, M.D. Anderson Cancer Center, University of Texas, Houston, TX

1060

A Common Genetic Variant in the 3’UTR of IRF4/MUM1 Associates with Risk of Disease and Poor Prognosis in Chronic Lymphocytic Leukaemia

James M Allan¹, Nicola Sunter²^*, Andrew Hall², Tryfonia Mainou-Fowler²^*, Graham Jackson³^*, Geoffrey Summerfield⁴^*, Robert John Harris, PhD⁵^*, Andrew Pettitt⁶^*, Richard Houlston⁷^*, James Bailey⁸^*, Chris Pepper⁹^*, Chris Fegan¹⁰^*, Guy Pratt¹¹ and David J Allsup, MRCP., MRCPath., PhD.¹²^*

¹Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom
²Newcastle University, Newcastle upon Tyne, United Kingdom
³Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom
⁴Queen Elizabeth Hospital, Gateshead, United Kingdom
⁵Haematology, University of Liverpool, Liverpool, United Kingdom
⁶University of Liverpool, Liverpool, United Kingdom
⁷Institute of Cancer Research, Sutton, United Kingdom
⁸University of Hull, Hull, United Kingdom
⁹Cardiff University, Cardiff, United Kingdom
¹⁰Cardiff and Vale NHS Trust, Cardiff, United Kingdom
¹¹Birmingham Heartlands Hospital, Birmingham, United Kingdom
¹²Department of Haematology, Hull Royal Infirmary, Hull, United Kingdom

1061

Genome-Wide DNA Copy Number Analysis by SNP Arrays of B-Cell Chronic Lymphocytic Leukemia: Correlation with Known Biological and Molecular Prognostic Markers

Laura Mosca, PhD¹^*, Sonia Fabris, PhD¹^*, Giovanna Cutrona, PhD²^*, Luca Agnelli¹^*, Serena Matis, PhD²^*, Massimo Gentile, PhD³^*, Mauro Spriano, PhD⁴^*, Vincenzo Callea, MD⁵^*, Gianluca Festini, PhD⁶^*, Stefano Molica, MD⁷, Caterina Mammi, PhD⁸^*, Massimo Federico, PhD⁸^*, Giorgio Lambertenghi Deliliers, MD¹, Fortunato Morabito, MD³^*, Manlio Ferrarini, MD⁹^* and Antonino Neri, MD¹^*

¹Department of Medical Science, Leukemia Study Center - Hematology 1, C.T.M.O., University of Milan - Fondazione IRCCS Policlinico, Milan, Italy
²Medical Oncology Center, IST Genova, Genova, Italy
³O.U. Haematology, Azienda Ospedaliera "Annunziata", Cosenza, Italy
⁴Haematology Department, San Martino Hospital, Genova
⁵Haematology Department, Azienda Ospedaliera, Reggio Calabria
⁶Medicine II, Haematology Center, Azienda Ospedalieria Universitaria, Trieste
⁷Oncology/Haematology Department, Azienda Ospedaliera "Pugliese-Ciaccio", Catanzaro, Italy
⁸Oncology/Haematology Department, University of Modena, Modena, Italy
⁹Medical Oncology Center - Oncology, Biology and Genetic Department, IST Genova - University of Genova, Genova, Italy

1062

Biological and Clinical Relevance of Surrogate Markers of IgVH Mutational Status in B-Cell Chronic Lymphocytic Leukemia

Fortunato Morabito, MD¹^*, Marta Lionetti, PhD²^*, Giovanna Cutrona, PhD³^*, Katia Todoerti, PhD²^*, Serena Matis, PhD³^*, Massimo Gentile, PhD¹^*, Mauro Spriano, PhD⁴^*, Vincenzo Callea, MD⁵^*, Gianluca Festini, PhD⁶^*, Stefano Molica, MD⁷, Giorgio Lambertenghi Deliliers, MD⁸, Manlio Ferrarini, MD⁹^* and Antonino Neri, MD²^*

¹O.U. Haematology, Azienda Ospedaliera Annunziata, Cosenza, Italy
²Department of Medical Science, Leukemia Study Center - Hematology 1, C.T.M.O., University of Milan - Fondazione IRCCS Policlinico, Milan, Italy
³Medical Oncology C, IST Genova, Genova, Italy
⁴O.U. Haematology, San Martino Hospital, Genova, Italy
⁵Haematology Department, Azienda Ospedaliera "Bianchi-Melacrinò-Morelli", Reggio Calabria, Italy
⁶Medicine II, Haematology Center, Azienda Ospedalieria Universitaria, Trieste
⁷Oncology/Hematology, Azienda Ospedaliera "Pugliese-Ciaccio", Catanzaro, Italy
⁸Department of Medical Science, Leukemia Study Center - Hematology 1, C.T.M.O., University of Milan - Fondazione IRCCS Policlinico, Milano, Italy
⁹Medical Oncology Center - Oncology, Biology and Genetic Department, IST Genova - University of Genova, Genova, Italy

1063

Molecular Characteristic of Variant and Classic Hairy Cell Leukemia

Evgeny Arons, PhD¹, Tara Suntum¹^*, Joel Sunshine¹^*, Anna Orthwein¹^*, Inger Margulies¹^*, Maryalice Stetler-Stevenson, MD, PhD² and Robert Kreitman, MD³

¹Lab. of Molecular Biology, National Cancer Institute/NIH, Bethesda, MD
²Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, MD
³National Institutes of Health, Bethesda, MD

1064

Aberrant Regulation of pVHL Levels by Microrna May Explain Autocrine Secretion of VEGF in CLL B Cells

Asish K Ghosh, PhD¹, Tait Shanafelt, MD², George A Calin, MD, PhD³^*, Carlo M. Croce, MD⁴, Linda Wellik²^*, Debabrata Mukhopadhyay¹^* and Neil Kay¹^*

¹Hematology, Mayo Clinic, Rochester, MN
²Mayo Clinic, Rochester, MN
³Experimental Therapeutics and Cancer Genetics, University of Texas, MD Anderson Cancer Center, Houston, TX
⁴The Ohio State University Comprehensive Cancer Center, Columbus, OH

1065

Enhanced Formation and Survival of Regulatory T Cells in CLL

Margot Jak¹^*, Rogier Mous¹^*, Ester BM Remmerswaal²^*, René Spijker¹^*, Annelieke Jaspers¹^*, Adriana Yagüe³^*, Eric Eldering¹^*, René A.W. van Lier²^* and Marinus H. J. van Oers³

¹Department of Hematology and Experimental Immunology, Academic Medical Center, Amsterdam, Netherlands
²Department of Experimental Immunology, Academic Medical Center, Amsterdam, Netherlands
³Department of Hematology, Academic Medical Center, Amsterdam, Netherlands

1066

MicroRNA-29c and 223 Are Powerful Prognostic Factors for Chronic Lymphocytic Leukemia and Improve Risk Stratification When Combined with ZAP70 and LPL in a qPCR Score

Basile Stamatopoulos¹^*, Nathalie Meuleman¹, Dominique Bron¹, Benjamin Haibe-Kains²^*, Pascale Saussoy³^*, Philippe Martiat¹ and Laurence Lagneaux¹^*

¹Dept. of Experimental Hem., Jules Bordet Institute, Brussels, Belgium
²Functional Genomics and Translational Research Unit, Jules Bordet Institute, Brussels, Belgium
³Dept. of hematological Biology, Cliniques Universitaires Saint-Luc, Brussels, Belgium

1067

Validation of CLL FISH Panel Scoring by Members of the Chronic Lymphocytic Leukemia Research Consortium

Stephanie A. Smoley¹^*, Daniel L. Van Dyke¹, Neil E. Kay²^*, Nyla A. Heerema³, Marie L. dell' Aquila⁴^*, Prasad Koduru⁵, Paola Dal Cin⁶^*, Laura Rassenti⁷, John C. Byrd⁸, Kanti R. Rai⁹, Jennifer R. Brown¹⁰, Andrew W Greaves⁴^*, Thomas J. Kipps¹¹ and Gordon W. Dewald¹

¹Mayo Clinic, Rochester, MN
²Hematology/Oncology division, Mayo Clinic, Rochester, MN
³Ohio State University, Columbus, OH
⁴University of California San Diego, San Diego, CA
⁵North Shore Hospital, Manhasset, NY
⁶Brigham & Women's Hospital, Boston, MA
⁷Medicine, Moores UCSD Cancer Center, La Jolla, CA
⁸The Ohio State University, Columbus, OH
⁹Long Island Jewish Med. Ctr., New Hyde Park, NY
¹⁰Dana-Farber Cancer Inst., Boston, MA
¹¹Univ. of California, San Diego, La Jolla, CA

1068

Clinical Outcome of Chronic Lymphocytic Leukemia Patients with Sole 13q FISH Detectable Defects: One Versus Two 13q Deletions

Daniel L. Van Dyke¹, Tait D. Shanafelt¹, Timothy G. Call¹, Clive S. Zent¹, Stephanie A. Smoley¹^*, Kari G. Rabe¹^*, Susan M. Schwager¹^*, Jessica C. Sonbert²^* and Neil E. Kay³^*

¹Mayo Clinic, Rochester, MN
²Division of Hematology, Mayo Clinic, Rochester, MN
³Hematology, Mayo Clinic, Rochester, MN

1069

Chronic Lymphocytic Leukemia (CLL) Cells Require Microenvironmental Stimuli to Resist Apoptosis through Activation of STAT3 Mediated by VEGF

Iris Gehrke, M.Sc.¹^*, Julian Paesler, M.Pharm.¹^*, Rajesh Kumar Gandhirajan, M.Sc.¹^*, Regina Razavi, M.Pharm.¹^*, Alexandra Filipovich¹^*, Felix Erdfelder¹^*, Magdalena Hertweck¹^*, Michael Hallek, MD² and Karl Anton Kreuzer, M.D.¹^*

¹Department I of Internal Medicine, Center of Integrated Oncology Cologne-Bonn, University at Cologne, Cologne, Germany
²Department I of Internal Medicine, Center of Integrated Oncology Cologne Bonn, University of Cologne, Cologne, Germany

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

641.P1.92 Chronic Lymphocytic Leukemia - Biology and Pathophysiology, Excluding Therapy Poster I